

Åmer KÃ¼Å§Ã¼k

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4671996/publications.pdf>

Version: 2024-02-01

64
papers

1,041
citations

471371

17
h-index

477173

29
g-index

66
all docs

66
docs citations

66
times ranked

1716
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of inflammation by phytochemicals to enhance efficacy and reduce toxicity of cancer chemotherapy. <i>Critical Reviews in Food Science and Nutrition</i> , 2023, 63, 2494-2508.	5.4	14
2	Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 53-59.	0.9	4
3	Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).. <i>Journal of Clinical Oncology</i> , 2022, 40, 544-544.	0.8	0
4	Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology.. <i>Journal of Clinical Oncology</i> , 2022, 40, 529-529.	0.8	4
5	Is vitamin A an antioxidant?. <i>International Journal for Vitamin and Nutrition Research</i> , 2022, , .	0.6	2
6	Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 271.e9-271.e18.	0.8	6
7	Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, , .	0.6	1
8	Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 30-34.	0.9	8
9	Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 319-339.	2.7	22
10	Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100393.	0.7	2
11	Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. <i>Theranostics</i> , 2021, 11, 6873-6890.	4.6	21
12	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, 397-405.	1.9	14
13	Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1714.	5.8	70
14	Epigenetic alterations and genetic variations of angiotensin-converting enzyme 2 (ACE2) as a functional receptor for SARS-CoV-2: potential clinical implications. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1587-1598.	1.3	10
15	Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 701345.	1.3	4
16	Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. <i>Oncologist</i> , 2021, 26, 956-964.	1.9	7
17	Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 707050.	1.3	19
18	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12

#	ARTICLE	IF	CITATIONS
19	Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e193-e199.	0.9	1
20	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, 1017-1025.	1.9	18
21	IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002903.		36
22	EDITORIAL COMMENT. <i>Urology</i> , 2021, 156, 209-210.	0.5	0
23	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 218-229.	1.0	1
24	Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. <i>Neoplasia</i> , 2021, 23, 1261-1274.	2.3	4
25	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e484-e491.	1.9	29
26	TGF-Î² causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. <i>Theranostics</i> , 2020, 10, 7656-7670.	4.6	34
27	Novel small molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 993-1005.	1.2	2
28	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2020, 9, 2752-2760.	1.3	13
29	Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 622134.	1.3	4
30	25â€¦Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies. , 2020, 8, A277-A278.		1
31	Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI).. <i>Journal of Clinical Oncology</i> , 2020, 38, 563-563.	0.8	1
32	Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).. <i>Journal of Clinical Oncology</i> , 2020, 38, 738-738.	0.8	1
33	A risk scoring system for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line abiraterone (ABA) or enzalutamide (ENZ).. <i>Journal of Clinical Oncology</i> , 2020, 38, 51-51.	0.8	0
34	Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models. <i>Cancer Letters</i> , 2019, 446, 62-72.	3.2	10
35	Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541983531.	0.8	43
36	Tomato Powder Modulates NF-Î², mTOR, and Nrf2 Pathways during Aging in Healthy Rats. <i>Journal of Aging Research</i> , 2019, 2019, 1-8.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinomaâ€”A single institution analysis of 54 patients. <i>Clinical Otolaryngology</i> , 2019, 44, 639-643.	0.6	5
38	Genistein Prevents Development of Spontaneous Ovarian Cancer and Inhibits Tumor Growth in Hen Model. <i>Cancer Prevention Research</i> , 2019, 12, 135-146.	0.7	36
39	Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 473-473.	0.8	2
40	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e563-e575.	0.9	72
41	The addition of chemotherapy in the definitive management of high risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 475-487.	0.8	6
42	A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. <i>Neoplasia</i> , 2018, 20, 789-799.	2.3	23
43	Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1859-1870.	1.9	19
44	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11257.	0.5	9
45	Lycopene in the Prevention of Radiation-Induced Esophagitis. <i>Nutrition and Cancer</i> , 2017, 69, 319-329.	0.9	10
46	Soy foods, isoflavones, and breast cancer. <i>Cancer</i> , 2017, 123, 1901-1903.	2.0	34
47	Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770551.	0.8	13
48	A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. <i>Asian Journal of Urology</i> , 2017, 4, 230-238.	0.5	13
49	Impact of ¹⁸ F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. <i>Journal of Nuclear Medicine</i> , 2017, 58, 412-418.	2.8	36
50	Effects of genistein supplementation on genome-wide DNA methylation and gene expression in patients with localized prostate cancer. <i>International Journal of Oncology</i> , 2017, 51, 223-234.	1.4	61
51	Biomarker study of early death in patients with intermediate and favorable risk metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 530-530.	0.8	0
52	Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer. <i>Anticancer Research</i> , 2017, 37, 6235-6243.	0.5	4
53	Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative. <i>Oncotarget</i> , 2016, 7, 27489-27498.	0.8	8
54	A novel preoperative inflammatory marker prognostic score in patients with clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 566-566.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Cancer biomarkers. <i>Molecular Aspects of Medicine</i> , 2015, 45, 1-2.	2.7	9
56	Carotenoids and non-alcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 161-71.	0.7	36
57	Orally Administered Lycopene Attenuates Diethylnitrosamine-Induced Hepatocarcinogenesis in Rats by Modulating Nrf-2/HO-1 and Akt/mTOR Pathways. <i>Nutrition and Cancer</i> , 2014, 66, 590-598.	0.9	50
58	External validation of the modified Glasgow prognostic score for renal cancer. <i>Indian Journal of Urology</i> , 2014, 30, 33.	0.2	26
59	Tomato powder impedes the development of azoxymethane-induced colorectal cancer in rats through suppression of COX-2 expression via NF- κ B and regulating Nrf2/HO-1 pathway. <i>Molecular Nutrition and Food Research</i> , 2012, 56, 1477-1481.	1.5	16
60	Utility of the modified Glasgow prognostic score in patients with metastatic renal cell carcinoma treated with targeted agents.. <i>Journal of Clinical Oncology</i> , 2012, 30, 441-441.	0.8	5
61	Genistein Protects Hematopoietic Stem Cells Against G-CSF Induced DNA Damage. <i>Blood</i> , 2012, 120, 3486-3486.	0.6	0
62	Genistein Protects Against DNA Damage in Hematopoietic Stem Cells,. <i>Blood</i> , 2011, 118, 3437-3437.	0.6	0
63	Lycopene and Chemotherapy Toxicity. <i>Nutrition and Cancer</i> , 2010, 62, 988-995.	0.9	40
64	Lycopene in Cancer Prevention and Treatment. <i>American Journal of Therapeutics</i> , 2008, 15, 66-81.	0.5	80